Urapidil, a dual-acting antihypertensive agent: Current usage considerations

Advances in Therapy

Volumn 27, Issue 7, 2010, Pages 426-443

  Buch, Jan ^a  

^a NONE   (Denmark)

Author keywords

alpha 1 adrenoreceptor antagonists; blood pressure; hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIHYDRALAZINE; ENALAPRILAT; HYDROCHLOROTHIAZIDE; METOPROLOL; NIFEDIPINE; NITROPRUSSIDE SODIUM; PLACEBO; PRAZOSIN; SEROTONIN 1A RECEPTOR; THIAZIDE DIURETIC AGENT; URAPIDIL;

ADD ON THERAPY; ADRENERGIC ACTIVITY; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEADACHE; HEART PALPITATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTENSIVE CRISIS; INSULIN RESISTANCE; LIPID METABOLISM; LONG TERM CARE; MATERNAL HYPERTENSION; NAUSEA; NEUROPROTECTION; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPERTENSION; PREECLAMPSIA; REVIEW; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

EID: 77956209594     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0039-0     Document Type: Review

References (89)

1. Ezzati M, Lopez A, Rodgers A, Vander Hoorn S, Murray CJL, eds. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization; 2004.
2. A.V. Chobanian 2009 Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy N Engl J Med 361 878 887 10.1056/NEJMsa0903829 19710486 1:CAS:528:DC%2BD1MXhtVKhtL3I
3. K. Wolf-Maier R.S. Cooper H. Kramer 2004 Hypertension treatment and control in five European countries, Canada, and the United States Hypertension 43 10 17 10.1161/01.HYP.0000103630.72812.10 14638619 1:CAS:528: DC%2BD3sXpvVeqtr8%3D
4. M. Thoenes H.R. Neuberger M. Volpe B.V. Khan W. Kirch M. Böhm 2010 Antihypertensive drug therapy and blood pressure control in men and women: an international perspective J Hum Hypertens 24 536 544 10.1038/jhh.2009.76 1:CAS:528:DC%2BC3cXkvVGjt74%3D
5. R.L. Antikainen V.A. Moltchanov C. Chukwuma Sr 2006 WHO MONICA Project. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA roject Eur J Cardiovasc Prev Rehabil 13 13 29 10.1097/00149831- 200602000-00004 16449860
6. E. Falaschetti M. Chaudhury J. Mindell N. Poulter 2009 Continued improvement in hypertension management in England: results from the Health Survey for England 2006 Hypertension 53 480 486 10.1161/HYPERTENSIONAHA.108. 125617 19204180 1:CAS:528:DC%2BD1MXhs1CntLc%3D
7. G. Mancia G. De Backer A. Dominiczak 2007 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 1462 1536 17562668
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:(doi: 10.1136/bmj.b1665).
9. D. De Bacquer G. De Backer 2006 The prevalence of concomitant hypertension and hypercholesterolaemia in the general population Int J Hypertens 110 217 223
10. B.S. Heran B.P. Galm J.M. Wright 2009 Blood pressure lowering efficacy of alpha blockers for primary hypertension Cochrane Database Syst Rev 4 CD004643 19821331
11. R.M. Zusman 2000 The role of alpha 1-blockers in combination therapy for hypertension Int J Clin Pract 54 36 40 10750258 1:CAS:528:DC%2BD3cXhsVeiu7Y%3D
12. P.A. van Zwieten G.J. Blauw P. van Brummelen 1990 Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity Drugs 40 suppl.4 1 8 10.2165/00003495-199000404-00003 1982649
13. M. Dooley K.L. Goa 1998 Urapidil. A reappraisal of its use in the management of hypertension Drugs 56 929 955 10.2165/00003495-199856050-00016 9829161 1:CAS:528:DyaK1cXns12rsbs%3D
14. A. Zanchetti 1995 Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group Blood Press Suppl 3 38 46 8535541 1:STN:280:DyaK287is1Knsg%3D%3D
15. K. Mizuno S. Fukuchi 1991 Antihypertensive effectiveness of urapidil alone and in combination with nifedipine in mild to moderate essential hypertension Curr Ther Res 50 274 281
16. R. Fariello C. Dal Palu A. Pessina 1990 Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy Drugs 40 suppl.4 60 62 10.2165/00003495-199000404-00017 2092970
17. Y. Kaneko 1988 Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension Drugs 35 suppl.6 156 163 10.2165/00003495-198800356-00021 3042355
18. T. Takeda Y. Kaneko H. Shionoiri 1988 Urapidil in patients with severe hypertension and in long-term treatment J Hypertens Suppl 6 S37 42 2906699 1:STN:280:DyaL1M7lslWnsw%3D%3D
19. G. Mancia G. Grassi A. Zanchetti 2006 New-onset diabetes and antihypertensive drugs J Hypertens 24 3 10 10.1097/01.hjh.0000194119.42722.21 16331092 1:CAS:528:DC%2BD2MXht1yitLzE
20. W.J. Elliott P.M. Meyer 2007 Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis Lancet 369 201 207 10.1016/S0140-6736(07)60108-1 17240286 1:CAS:528:DC%2BD2sXntlCnsA%3D%3D
21. R. Fariello E. Boni L. Corda A. Zaninelli A. Noseda A. Spinazzi 1992 Influence of a new multifactorial antihypertensive on blood pressure and metabolic profile in essential hypertension associated with non-insulin- dependent diabetes mellitus Eur Heart J 13suppl.A 65 69
22. S. Oren S. Turkot E. Paran O. Flandra L. Slezak B. Hof 1996 Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM) J Hum Hypertens 10 123 127 8867567 1:STN:280:DyaK2s%2FitFajtQ%3D%3D
23. Y. Goto 1992 Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial Curr Ther Res 51 870 876
24. L.A. Ferrara G. Leonetti R. Fogari C. Mazzola M. Mancini A. Zanchetti 1994 Urapidil in hypercholesterolemic hypertensive patients Blood Press Suppl 4 39 44 7804511 1:STN:280:DyaK2M7gt12isA%3D%3D
25. J.W. Pattenier F.C. von Heusinger 1992 Effect of urapidil treatment on lipid metabolism in patients with hypertension Royal Soc Med Int Congr Symp 196 61 67
26. A. Gerber P. Weidmann C. Marone D. Uehlinger W. Riesen 1985 Cardiovascular and metabolic profile during intervention with urapidil in humans Hypertension 7 963 971 3908316 1:STN:280:DyaL28%2FosVegug%3D%3D
27. K. Held P. Cremer E. Hundertmark D. Seidel 1985 Effects of long-term antihypertensive therapy with Urapidil (EbrantilR) on lipometabolism Hochdruck 5 2
28. H. Liebau W. Wurst I. Harder P. Solleder 1988 Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil Fortschr Med 106 651 654 3148534 1:STN:280:DyaL1M7nt1Gquw%3D%3D
29. A. Haenni H. Lithell 1996 Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension Metabolism 45 1221 1229 10.1016/S0026-0495(96)90239-5 8843176 1:CAS:528:DyaK28XmtFGitrk%3D
30. E. Ernst K.L. Resch 1993 Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature Ann Intern Med 118 956 963 8489110 1:STN:280:DyaK3s3ls1ertQ%3D%3D
31. J. Danesh S. Lewington S.G. Thompson 2005 Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis JAMA 294 1799 1809 10.1001/jama.294.14.1799 16219884 1:CAS:528:DC%2BD2MXhtFWgsLnM
32. K. Sebekova V. Fedelesova P. Blazicek R. Dzurik 1990 Acute effect of urapidil on peripheral serotonin metabolism Cor Vasa 32 274 281 2225876 1:STN:280:DyaK3M%2FjtVKiuw%3D%3D
33. C.C. Smith D.J. Betteridge B.N. Prichard 1990 Platelet in vitro responses to urapidil and prazosin Drugs 40 suppl.4 48 51 10.2165/00003495-199000404- 00013 2092966 1:CAS:528:DyaK3MXkt1Wqsr8%3D
34. J. Storck J.G. Ochs R. Kirsten 1990 Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets Int J Clin Pharmacol Ther Toxicol 28 303 308 2387654 1:CAS:528:DyaK3cXls1Giu70%3D
35. K. Kawabe S. Tsuchida J. Shimazaki T. Morita K. Yasuda S. Kageyama 1993 Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study Urol Int 50 27 32 10.1159/000282443 7679532 1:STN:280:DyaK3s7ms1Gqug%3D%3D
36. K. Yasuda T. Yamanishi K. Kawabe H. Ohshima T. Morita 1996 The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study J Urol 156 1125 1130 10.1016/S0022-5347(01)65723-9 8709324 1:CAS:528:DyaK28Xltlahsrc%3D
37. T. Yamanishi K. Yasuda Y. Homma K. Kawabe T. Morita 1999 A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction Eur Urol 35 45 51 10.1159/000019818 9933794 1:CAS:528:DyaK1MXhvVSitLY%3D
38. T. Yamanishi K. Yasuda T. Kamai 2004 Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor Int J Urol 11 88 96 10.1111/j.1442-2042.2004.00753.x 14706012 1:CAS:528:DC%2BD2cXislalsLw%3D
39. Y. Ikeda N. Takagi K. Takeda 1992 Clinical evaluation of urapidil in hypertensive patients with renal failure Shinyaku to Rinsho 41 622 631
40. P.W. de Leeuw P.N. van Es H.A. de Bruyn W.H. Birkenhäger 1988 Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man Drugs 35 suppl.6 74 77 10.2165/00003495-198800356-00010 2900132
41. A.T. Lavrijssen A.A. Kroon M. Fuss-Lejeune P.M. Schiffers P.W. de Leeuw 2000 Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension J Hypertens 18 963 969 10.1097/00004872-200018070-00019 10930195 1:CAS:528:DC%2BD3cXlsFGmtr8%3D
42. H. Liebau W. Wurst I. Harder P. Solleder 1988 Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil Fortschr Med 106 651 654 3148534 1:STN:280:DyaL1M7nt1Gquw%3D%3D
43. H. Liebau P. Solleder I. Harder W. Wurst 1990 Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness Fortschr Med 108 325 328 2118878 1:STN:280:DyaK3cznsFWmtA%3D%3D
44. R. Haerlin 1985 Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil®) Clinical Trials J 22 215 225
45. D. Cherney S. Straus 2002 Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature J Gen Intern Med 17 937 945 10.1046/j.1525-1497.2002.20389.x 12472930
46. M.I. Perez V.M. Musini 2008 Pharmacological interventions for hypertensive emergencies Cochrane Database Syst Rev 1 CD003653 18254026
47. Agence Française de Sécurité Sanitaire Des Produits de Santé 2002 Poussees hypertensives de l'adulte: elevation tensionnelle sans souffrance viscerale immediate et urgences hypertensives Agence Française de Sécurité Sanitaire Des Produits de Santé Saint Denis, France
48. Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS). Poussees hypertensives de l'adulte: elevation tensionnelle sans souffrance viscerale immediate et urgences hypertensives [in French]. Agence Française de Sécurité Sanitaire Des Produits de Santé, Saint Denis, France, May 2002. Available at
49. J. Slany D. Magometschnigg G. Mayer 2007 Klassifikation, Diagnostik und Therapie der Hypertonie 2007 - Empfehlungen der Österreichischen Gesellschaft für Hypertensiologie J Hypertonie 11 7 11
50. J. Zähringer M. Klepzig J. Greif B. Ludwig B. Strauer 1984 Therapy of the hypertensive crisis with urapidil. Various effects on patients with or without coronary disease Fortschr Med 102 624 628 6469170
51. K. Błaszyk S. Grajek W. Skorupski 1995 Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies [in Polish] Pol Arch Med Wewn 94 512 517 8618814
52. J. Alijotas-Reig I. Bove-Farre F. de Cabo-Frances R. Angles-Coll 2001 Effectiveness and safety of prehospital urapidil for hypertensive emergencies Am J Emerg Med 19 130 133 10.1053/ajem.2001.20008 11239257 1:STN:280: DC%2BD3M7psl2ltw%3D%3D
53. B. Jelakovic M. Grba-Bujevic I. Bosan-Kilibarda 2009 Hypertensive crisis. Efficacy and safe of urapidil based protocol in out-of-hospital settings J Hypertens 27 suppl.4 S122
54. M.M. Hirschl D. Seidler A. Zeiner 1993 Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies Am J Emerg Med 11 653 656 10.1016/0735-6757(93)90026-8 8240575 1:STN:280:DyaK2c%2FlvFamtQ%3D%3D
55. M.M. Hirschl D. Seidler M. Müllner 1996 Efficacy of different antihypertensive drugs in the emergency department J Hum Hypertens 10 suppl.3 S143 146 8872847
56. M.M. Hirschl M. Binder A. Bur 1997 Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies Intensive Care Med 23 885 888 10.1007/s001340050426 9310807 1:STN:280:DyaK2svls1ymsw%3D%3D
57. C. Woisetschläger A. Bur M. Vlcek U. Derhaschnig A.N. Laggner M.M. Hirschl 2006 Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies J Hum Hypertens 20 707 709 10.1038/sj.jhh.1002063 16826189 1:CAS:528:DC%2BD28XosVSjsr0%3D
58. F. Späh K.D. Grosser G. Thieme 1990 Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies Drugs 40 suppl.4 58 59 10.2165/00003495-199000404-00016 2092969
59. J. Wacker P. Werner I. Walter-Sack G. Bastert 1998 Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil Nephrol Dial Transplant 13 318 325 10.1093/ndt/13.2.316 9509441 1:CAS:528:DyaK1cXhsF2ksbo%3D
60. J.R. Wacker B.K. Wagner V. Briese 2006 Antihypertensive therapy in patients with preeclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil Eur J Obstet Gynecol Reprod Biol 127 160 165 10.1016/j.ejogrb.2005.09.013 16253414 1:CAS:528:DC%2BD28XotV2nurc%3D
61. M. Schulz J. Wacker G. Bastert 2001 Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns [in German] Zentralbl Gynakol 123 529 533 10.1055/s-2001-18226 11709746 1:STN:280: DC%2BD3MnmtlWitA%3D%3D
62. Deutsche Hochdruckliga e.V. DHLR - Deutsche Hypertonie Gesellschaft. Leitlinien zur behandlung der arteriellen hypertonie. Heidelberg, Germany, 2008. Available at: www.hochdruckliga.de. Accessed: May 24, 2010.
63. M. Olmos M.A. Vidarte J.A. Ballester J. Lasuen A. Escobar 2000 Efficacy of a single dose of urapidil for preventing arterial hypertension during the pre-bypass period in coronary surgery Rev Esp Anestesiol Reanim 47 337 342 11103114 1:STN:280:DC%2BD3M%2FosFWjsg%3D%3D
64. E. Gob A. Barankay J.A. Richter 1981 Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine Arzneimittelforschung 31 1479 1481 7197959 1:STN:280:DyaL38%2FmvVKrsA%3D%3D
65. W. Hess 1990 Urapidil versus clonidine. Acute haemodynamic effects during control of intraoperative hypertensive episodes Drugs 40 suppl.4 77 79 10.2165/00003495-199000404-00024 2092976
66. W. Hess U. Schulte-Sasse J. Tarnow S. Veit 1985 Comparison of phentolamine and urapidil in controlling acute intra-operative hypertension in patients subjected to coronary artery bypass surgery Eur J Anaesthesiol 2 21 27 3874774 1:STN:280:DyaL2M3lslGmtw%3D%3D
67. A. Petry H. Wulf M. Baumgartel 1995 The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation Anaesthesia 50 312 316 10.1111/j.1365-2044. 1995.tb04606.x 7747847 1:STN:280:DyaK2M3ms1Ojsw%3D%3D
68. J.G. van der Stroom H.B. Van Wezel J.J. Koolen C.A. Visser P.A. Van Zwieten 1994 Comparison of the effects of urapidil and nitroprusside on hemodynamics and myocardial function in hypertension following cardiac surgery Blood Press Suppl 4 31 38 7804510
69. J.G. van der Stroom H.B. van Wezel J.J. Langemeijer 1997 A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery J Cardiothorac Vasc Anesth 11 729 736 10.1016/S1053-0770(97)90166-X 9327314
70. J.G. van der Stroom H.B. van Wezel I. Vergroesen 1996 Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery Br J Anaesth 76 645 651 8688263
71. T. Mollhoff H. Van Aken J.P. Mulier E. Muller P. Lauwers 1990 Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting Br J Anaesth 64 493 497 10.1093/bja/64.4.493 2334625 1:STN:280:DyaK3c3ktFOksw%3D%3D
72. J. van Hemelrijck P. Waets H. van Aken H. Lacroix A. Nevelsteen R. Suy 1993 Blood pressure management during aortic surgery - Urapidil compared to isosorbide dinitrate J Cardiothorac Vasc Anesth 7 273 278 10.1016/1053-0770(93) 90004-5 8518372
73. J. Zander C. Puchstein H. van Aken P. Lawin 1984 Urapidil as a supplement to neuroleptanalgesia during neuroanaesthesia Br J Anaesth 56 1304 1305
74. C. Puchstein H. Van Aken J. Zander P. Lawin 1984 The use of urapidil in the postoperative period Anaesthesist 33 224 227 6465511 1:STN:280: DyaL2c3nvVeitQ%3D%3D
75. P. Gosse P. Tauzin-Fin M.B. Sesay A. Sautereau P. Ballanger 2009 Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose J Hum Hypertens 23 605 609 10.1038/jhh.2008.172 19225531 1:CAS:528:DC%2BD1MXhtValtr3E
76. F. Spah S.O. Walsemann 1995 Potential beneficial effects of urapidil in primary and secondary prevention of stroke Blood Press Suppl 3 62 67 8535545 1:STN:280:DyaK287is1KnsQ%3D%3D
77. R. Wusten J. Hemelrijck M. Mattheussen T. Lauvers C. Anger H. van Aken 1990 Der einfluss von nifidepin und urapidil auf die autoregulation der zerebralen durchbtuling in gegenwart einer intrakraniellen raumforderung Anasth Intensivther Notfallmed 25 140 145 10.1055/s-2007-1001037 2360708 1:STN:280:DyaK3c3pslekug%3D%3D
78. J.H. Prehn C. Backhauss C. Karkoutly 1991 Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia Eur J Pharmacol 203 213 222 10.1016/0014-2999(91)90717-5 1800118 1:CAS:528:DyaK38XhsFKrug%3D%3D
79. European Stroke Initiative Executive Committee. 2003 European Stroke Initiative Recommendations for Stroke Management-update 2003 Cerebrovasc Dis 16 311 337 10.1159/000072554
80. C.S. Anderson Y. Huang J.G. Wang 2008 Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial Lancet Neurol 7 391 399 10.1016/S1474-4422(08)70069-3 18396107
81. ALLHAT Collaborative Research Group. 2000 Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 283 1967 1975 10.1001/jama.283.15.1967
82. ALLHAT officerscoordinators for the ALLHAT Collaborative Research Group. 2003 Diuretics versus alpha blockers as first-step antihypertensive therapy Hypertension 42 239 246 10.1161/01.HYP.0000086521.95630.5A 1:CAS:528: DC%2BD3sXmslSju70%3D
83. A.V. Chobanian G.L. Bakris H.R. Black Joint National Committee on Prevention, Detection, Evaluation,Treatment of High Blood Pressure. National Heart, Lung,Blood Institute; National High Blood Pressure Education Program Coordinating Committee 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 1206 1252 10.1161/01.HYP.0000107251.49515.c2 14656957 1:CAS:528:DC%2BD3sXpsVGisL4%3D
84. N. Chapman C.L. Chang B. Dahlöf 2008 Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial Circulation 118 42 48 10.1161/CIRCULATIONAHA.107.737957 18559700 1:CAS:528:DC%2BD1cXnsFKqsrY%3D
85. R. Spoladore R. Roccaforte G. Fragasso 2009 Safety and efficacy of doxazosin as "add-on" antihypertensive therapy in mild to moderate heart failure patients Acta Cardiol 64 485 491 10.2143/AC.64.4.2041613 19725441
86. G.G. Belz J.H. Matthews D. Graf 1985 Dynamic responses to intravenous urapidil and dihydralazine in normal subjects Clin Pharmacol Ther 37 48 54 3880685 1:CAS:528:DyaL2MXhtVGqtb4%3D
87. Kobrin I, Amodeo C, Ventura HO, Messerli FH, Frohlich ED. Immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol. 1985:722-725.
88. K. Stoschitzky G. Stoschitzky M. Wonisch H. Brussee 2007 Differential effects of urapidil and doxazosin on heart rate Eur J Clin Pharmacol 63 259 262 10.1007/s00228-006-0256-2 17225141 1:CAS:528:DC%2BD2sXhsV2juro%3D
89. L. Hansson A. Petitet 1995 Review of studies with urapidil in elderly hypertensives Blood Press Suppl 3 21 25 8535538 1:STN:280:DyaK287is1KgtQ%3D%3D